Bupropion as a modulator of drug activity

Abstract

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

1 - 20 . (canceled) 
     
     
         21 . A method of treating major depressive disorder, comprising administering a dosage form by mouth once daily or twice daily to a human patient in need thereof, wherein the dosage form comprises a bupropion and a dextromethorphan as the only therapeutically active compounds in the dosage form. 
     
     
         22 . The method of claim  1 , wherein the dosage form is a tablet. 
     
     
         23 . The method of claim  1 , wherein bupropion hydrochloride is in a sustained release formulation. 
     
     
         24 . The method of claim  3 , wherein the dextromethorphan salt is in an immediate release formulation. 
     
     
         25 . The method of claim  1 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the C max  of bupropion in the human patient is about 9×10 1  ng/mL. 
     
     
         26 . The method of claim  1 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the AUC 0-12  of bupropion in the human patient is about 7×10 2  ng·hr/mL. 
     
     
         27 . The method of claim  1 , wherein the dextromethorphan salt is dextromethorphan hydrobromide. 
     
     
         28 . The method of claim  7 , wherein the dosage form is a tablet. 
     
     
         29 . The method of claim  7 , wherein bupropion hydrochloride is in a sustained release formulation. 
     
     
         30 . The method of claim  9 , wherein dextromethorphan hydrobromide is in an immediate release formulation. 
     
     
         31 . The method of claim  7 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the C max  of bupropion in the human patient is about 9×10 1  ng/mL. 
     
     
         32 . The method of claim  7 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the AUC 0-12  of bupropion in the human patient is about 7×10 2  ng·hr/mL. 
     
     
         33 . The method of claim  7 , wherein the human patient is an extensive CYP2D6 metabolizer. 
     
     
         34 . The method of claim  13 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter. 
     
     
         35 . The method of claim  1 , wherein the human patient is an extensive CYP2D6 metabolizer. 
     
     
         36 . The method of claim  15 , wherein the dosage form is a tablet. 
     
     
         37 . The method of claim  15 , wherein bupropion hydrochloride is in a sustained release formulation. 
     
     
         38 . The method of claim  17 , wherein the dextromethorphan salt is in an immediate release formulation. 
     
     
         39 . The method of claim  15 , wherein the dosage form administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the C max  of bupropion in the human patient is about 9×10 1  ng/mL. 
     
     
         40 . The method of claim  15 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the AUC 0-12  of bupropion in the human patient is about 7×10 2  ng·hr/mL.